Fate therapeutics announces expansion of solid tumor collaboration with ono pharmaceutical for off-the-shelf, ipsc-derived car nk and car t-cell cancer immunotherapies

Ono to contribute novel binding domains for a second solid tumor antigen to the collaboration

FATE Ratings Summary

FATE Quant Ranking